National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer

The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective and statistical details are given in the Protocol.

Study Overview

• Status: Active, not recruiting
• Conditions: Adenocarcinoma; Carcinoma, Squamous Cell; Non-Small Cell Lung Cancer
• Intervention / Treatment: Drug: Palbociclib; Drug: AZD6738; Drug: AZD4547; Drug: Vistusertib; Drug: Crizotinib; Drug: Selumetinib; Drug: Docetaxel; Drug: AZD5363; Drug: Osimertinib; Drug: Durvalumab; Drug: Sitravatinib

Detailed Description

The trial is primarily an enrichment putative biomarker design, including patients who are positive for at least one of the actionable targets included in the trial. Patients who are positive for just one putative biomarker will receive the experimental targeted drug specific for that putative biomarker. Putative biomarkers within each drug cohort have been chosen such that in the majority of cases it is not expected that patients will be positive for two or more putative biomarkers within the same drug. In the rare situation that patients are positive for two or more putative biomarkers relevant across different drugs, treatment will be allocated in accordance with the following strategy:

• All amplifications and rearrangements will be treated with targeted agent appropriate to them irrespective of concomitant mutations. This will yield crucial predictive biomarker information.
• For concomitant mutations decisions will be made by the Chief Investigator on a case-by-case basis and based on close consideration of pathway preference and likely dominance of one signal pathway over another together with any pre-clinical efficacy studies that address the activity of the drugs in the presence of concomitant mutations. A trumping strategy has been devised for this purpose.

• Study Type: Interventional
• Enrollment (Actual): 423
• Phase: Phase 2

Contacts and Locations

Study Locations

• United Kingdom
  • Aberdeen, United Kingdom
    • Aberdeen Royal Infirmary
  • Belfast, United Kingdom
    • Belfast City Hospital, Belfast Health and Social Care Trust
  • Birmingham, United Kingdom
    • Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust
  • Birmingham, United Kingdom, B15 2GW
    • Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust
  • Bristol, United Kingdom
    • University Hospitals Bristol NHS Foundation Trust
  • Cambridge, United Kingdom, CB2 0QQ
    • Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
  • Cardiff, United Kingdom, CF14 2TL
    • Velindre Cancer Centre, Velindre NHS Trust
  • Colchester, United Kingdom
    • Colchester General Hospital
  • Edinburgh, United Kingdom, EH4 2XU
    • Edinburgh Cancer Centre, Western General Hospital
  • Exeter, United Kingdom
    • Royal Devon and Exeter Hospital
  • Glasgow, United Kingdom, G12 0YN
    • Beatson West of Scotland Cancer Centre
  • Leeds, United Kingdom, LS9 7TF
    • St. James' University Hospital, Leeds Teaching Hospital NHS Trust
  • Leicester, United Kingdom
    • Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust
  • London, United Kingdom
    • Charing Cross Hospital, Imperial College Healthcare NHS Trust
  • London, United Kingdom, SW3 6JJ
    • Royal Marsden Hospital, The Royal Marsden NHS Foundation Trust
  • London, United Kingdom
    • Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust
  • London, United Kingdom
    • St Bartholomew's Hospital, Barts Health NHS Trust
  • London, United Kingdom
    • University College Hospital, University College London Hospitals NHS Foundation Trust
  • Maidstone, United Kingdom
    • Maidstone Hospital
  • Manchester, United Kingdom
    • The Christie Hospital, The Christie NHS Foundation Trust
  • Newcastle, United Kingdom, NE7 7DN
    • Sir Bobby Robson Cancer Trial Research Centre, The Newcastle upon Tyne Hospitals
  • Oxford, United Kingdom
    • Churchill Hospital, Oxford University Hospitals NHS Foundation Trust
  • Sheffield, United Kingdom
    • Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust
  • Southampton, United Kingdom, SO16 6YD
    • Southampton General Hospital, University Hospital Southampton NHS Foundation Trust
  • Wirral, United Kingdom, CH63 4JY
    • Clatterbridge Cancer Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Core inclusion and exclusion criteria are presented below. Additional inclusion/exclusion criteria apply to each arm and are presented in the relevant arm supplements of the protocol.

Inclusion Criteria:

• Prior anti-cancer treatment:

  • Patients who refuse any standard of care first line therapy, are eligible to receive National Lung Matrix Trial treatment as first line therapy, providing they explicitly consent to this effect.
  • Patients who have previously consented to and received standard of care first line therapy must have completed all standard of care therapy that the treating oncologist thinks is appropriate. As a minimum patients must have failed one or more lines of treatment (either radiological documentation of disease progression or due to toxicity). Patients whose disease has increased in size but is not classed as progressive disease as per RECIST criteria, will be eligible. Patients with no change at all in dimension of disease (i.e. true stability) after first line therapy will not be eligible.
  • Patients who have progressed after surgical resection and adjuvant therapy will be eligible for entry without the need for the administration of first line metastatic therapy.
  • Patients will also be eligible without the necessity for first line regimen if they have relapsed within 6 months of completion of definitive chemoradiation.
• Consented and provided an adequate specimen to adequately characterise the molecular genotype of the tumour in the molecular pre-screening according to the molecular exclusion rules (see Section 6.4 for definition of an adequate sample).
• Histological or cytologically confirmed NSCLC stage III (not suitable for radical radiotherapy or surgery) or stage IV. This includes patients who may have abnormal histology, but IHC strongly support either squamous cell carcinoma (p63 positivity) or adenocarcinoma (Thyroid transcription factor 1 [TTF1] positivity). If a physician and pathologist are convinced after multi-disciplinary review that the patient has stage III or IV NSCLC but where all the IHC is negative and the morphology does not distinguish a specific sub-type, these patients will be eligible for non-histology specific cohorts.
• CT or MRI scan of head, chest and abdomen within 28 days of treatment demonstrating measurable disease as per RECIST version 1.1 (see Appendix 1: Response Evaluation Criteria in Solid Tumours Version 1.1). (The same imaging modality must be used throughout treatment).

• Adequate haematological function within 7 days of treatment.

  • Haemoglobin ≥ 90 g/L.
  • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.
  • Platelets ≥ 100 x 109/L.

• Adequate hepatic function within 7 days of treatment in patients with no liver metastasis (see arm specific entry criteria for adequate hepatic function in patients with liver metastases).

  • Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN). (Note that this will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of haemolysis or hepatic pathology), who may be allowed inclusion at the discretion of the local Investigator).
  • Alanine transferase (ALT) ≤ 2.5 x ULN.
  • Aspartate transferase (AST) ≤ 2.5 x ULN.

• Adequate renal function within 7 days of treatment.

  • Creatinine clearance (CLcr) >50 ml/min (measured or calculated by Cockcroft and Gault equation - see Appendix 4: Cockcroft Gault Formula - Creatinine Clearance). If calculated CLcr is <50 ml/min a direct measurement of glomerular filtration rate (GFR) such as EDTA may be performed. If the value is >50 ml/min the patient is eligible.
• Age ≥ 18 years.

• Females must agree to use adequate contraceptive measures (as defined in Section 6.3), should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:

  • Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments
  • Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
  • Women aged under 50 years old would be consider postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the post-menopausal range for the institution.
• Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.

Exclusion Criteria:

• Major surgery (excluding placement of vascular access) within 4 weeks prior to treatment.
• Nausea, vomiting, chronic gastrointestinal diseases (e.g. inflammatory bowel disease) that would preclude adequate absorption.
• Any psychological, familial, sociological or geographical condition hampering protocol compliance.
• Concurrent malignancies or invasive cancers diagnosed within past 3 years except for adequately treated basal cell carcinoma of the skin and in situ carcinoma of the uterine cervix.
• Judgement by the local Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
• Any unresolved toxicity of grade 2, 3 or 4 from previous treatment (excluding alopecia) at Registration (see CTCAE - Appendix 3: Common Toxicity Criteria Gradings).
• Patients who have previous symptomatic brain metastases or spinal cord compression are excluded unless they have had adequate treatment, no evidence of progression or symptoms, and have had no requirement for steroid treatment in the previous 28 days before commencement of trial treatment.
• Patients with asymptomatic brain metastases picked up at screening CT scan are not excluded providing that in the view of the local Investigator they do not require immediate radiotherapy or surgical intervention, and have had no requirement for steroid treatment in the previous 28 days before commencement of trial treatment.
• As judged by the local Investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus. Screening for chronic conditions is not required.
• Pregnant and lactating patients (patients of childbearing potential must have a negative pregnancy test prior to registration).

Cardiac exclusion criteria, performance status and prior treatment washout periods are detailed within the National Lung Matrix Trial arm-specific eligibility criteria.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

10

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A: AZD4547; AZD4547 - FGFR Inhibitor Route & Formulation: Oral, Tablets Strengths: 20 & 80mg Trial Dose & Schedule: 80 mg BD, Continuous dosing, 21 day cycle.	Drug: AZD4547; FGFR Inhibitor
Experimental: Arm B: Vistusertib (AZD2014); Vistusertib (AZD2014) - MTORC1/2 Inhibitor Route & Formulation: Oral, Tablets Strengths: 25mg Trial Dose & Schedule: 125 mg BD, Intermittent dosing (2 continuous days in 7), 28 day cycle.	Drug: Vistusertib; MTORC1/2 Inhibitor; Other Names: AZD2014
Experimental: Arm C: Palbociclib; Palbociclib - CDK4/6 Inhibitor Route & Formulation: Oral, Capsules Strengths: 75, 100 & 125mg Trial Dose & Schedule: 125 mg OD, Intermittent dosing (21 days on, 7 days off), 28 day cycle.	Drug: Palbociclib; CDK4/6 Inhibitor
Experimental: Arm D: Crizotinib; Crizotinib - ALK Inhibitor Route & Formulation: Oral, Capsules Strengths: 200 & 250mg Trial Dose & Schedule: 250 mg BD, Continuous dosing, 21 day cycle.	Drug: Crizotinib; ALK/MET/ROS1 Inhibitor
Experimental: Arm E: Selumetinib & Docetaxel; AZD6244 (Selumetinib) - MEK Inhibitor Route & Formulation: Oral, Capsules Strengths: 25mg Trial Dose & Schedule: 75 mg BD, Continuous dosing, 21 day cycle. Docetaxel - Chemotherapy Route & Formulation: IV infusion over 30-60 minutes, concentrate for solution for infusion. Trial Dose & Schedule: 75 mg/m2, 3-weekly, 21 day cycle.	Drug: Selumetinib; MEK Inhibitor; Other Names: AZD6244; Drug: Docetaxel; Taxane, anti-mitotic cytotoxic chemotherapy
Experimental: Arm F: AZD5363; AZD5363 - AKT Inhibitor Route & Formulation: Oral, Tablets Strengths: 80 & 200mg Trial Dose & Schedule: 480 mg BD, Intermittent dosing (4 days on, 3 days off), 28 day cycles.	Drug: AZD5363; AKT Inhibitor
Experimental: Arm G: Osimertinib (AZD9291); Osimertinib (AZD9291) - EGFRM+ and T790M+ Inhibitor Route & Formulation: Oral, Tablets Strengths: 80mg Trial Dose & Schedule: 80 mg OD, Continuous dosing, 21 day cycles.	Drug: Osimertinib; EGFRm+ T790M+ Inhibitor; Other Names: AZD9291
Experimental: Arm NA: Durvalumab (MEDI4736); Durvalumab (MEDI4736) - Anti-PDL1 Route & Formulation: IV Infusion, Lyophilized powder for solution for infusion Strengths: Vial containing 200mg Trial Dose & Schedule: 10 mg/kg IV, 2-weekly.	Drug: Durvalumab; Anti-PDL1; Other Names: MEDI4736
Experimental: Arm H: Sitravatinib; Sitravatinib - VEGFR Inhibitor Route & Formulation: Oral, Capsules Strengths: 10 & 40mg Trial Dose & Schedule: 120 mg OD, Continuous dosing, 21 day cycles.	Drug: Sitravatinib; VEGFR Inhibitor; Other Names: MGCD516
Experimental: Arm J: AZ6738 & Durvalumab; AZD6738 - ATR Inhibitor Route & Formulation: Oral, Tablets Strengths: 20mg, 80mg, 100mg Trial Dose & Schedule: 240 mg twice daily (BD) on days 15-28 of 28 day cycle. Durvalumab (MEDI4736) - Anti-PDL1 Route & Formulation: IV Infusion, Lyophilized powder for solution for infusion Strengths: Vial containing 500mg Trial Dose & Schedule: 1500mg on day 1 of each 28 day cycle	Drug: AZD6738; ATR inhibitor; Drug: Durvalumab; Anti-PDL1; Other Names: MEDI4736

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response (OR)	CT scans every 6 weeks from baseline until disease progression (Primary outcome for all Trial Arms except Arm C). Investigators expect patients to participate in the study for a maximum of 18 months, however cannot guarantee that some patients may participate over 18 months.	From baseline until disease progression, assessed up to 18 months.
Progression-free survival time (PFS)	Defined as the time from commencement of trial treatment to the date of CT scan when progressive disease first recorded or date of death without previously recorded progression (Primary Outcome for Arm C only). Patients who are alive with no recorded progression at the time of analysis will be censored at the date of the CT scan when they were last recorded with an evaluable measure that was not progression. Investigators expect patients to participate in the study for a maximum of 18 months, however, cannot guarantee that some patients may participate over 18 months.	From date of commencement of trial treatment to date of CT scan when progressive disease first recorded or date of death without previously recorded progression, assessed up to 18 months.
Durable clinical benefit (DCB)	A patient will be defined as experiencing DCB if they remain free of disease progression at their fourth CT or MRI scan since treatment start date, i.e. approximately 24 weeks, or at any scan after 24 weeks that shows the patient free of disease progression (co-primary outcome for all Trial Arms except Arm C & G)	From baseline until the first scan after 24 weeks showing the patient free of disease progression.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Best percentage change in sum of target lesion diameters (PCSD)	At each evaluation, the longest diameters of all selected target lesions will be measured and summed and the percentage change from the baseline measurement will be calculated. The best percentage change is the one that reflects either the greatest decrease or the least increase over the whole period of assessment. Investigators expect patients to participate in the study for a maximum of 18 months, however cannot guarantee that some patients may participate over 18 months.	From baseline until disease progression, assessed up to 18 months.
Time to Progression (TTP)	This is defined as the time from commencement of trial treatment to the date of the CT scan when progressive disease first recorded. Patients with no recorded progression at the time of analysis or who die without recorded progression will be censored at the date of the CT scan when they were last recorded with an evaluable measure that was not progression. Investigators expect patients to participate in the study for a maximum of 18 months, however cannot guarantee that some patients may participate over 18 months.	The time from commencement of trial treatment to the date of the CT scan when progressive disease first recorded, assessed up to 18 months.
Overall survival time (OS)	This is defined as the time of commencement of trial treatment to the date of death. Patients who are alive at the time of analysis will be censored at the date last seen alive. Investigators expect patients to participate in the study for a maximum of 18 months, however cannot guarantee that some patients may participate over 18 months.	From time of commencement of trial treatment until date of death, assessed up to 18 months.
Adverse Events (AE)	Adverse events will be recorded in relation to each cycle of treatment and graded according to Common Terminology Criteria for Adverse Events (CTCAE). The incidence of each adverse event (all grades and grade 3/4) will be reported as a per-patient-cycle rate and as a per-patient rate. Investigators expect patients to participate in the study for a maximum of 18 months, however cannot guarantee that some patients may participate over 18 months.	From date of informed consent to trial treatment until 28 days after the last administration of the last treatment, assessed up to 18 months.

Collaborators and Investigators

• Sponsor: University of Birmingham
• Collaborators: Pfizer; AstraZeneca; Mirati Therapeutics Inc.; Cancer Research UK; Experimental Cancer Medicine Centres
• Investigators: Principal Investigator: Gary W Middleton, University of Birmingham

Publications and helpful links

General Publications

• Middleton G, Crack LR, Popat S, Swanton C, Hollingsworth SJ, Buller R, Walker I, Carr TH, Wherton D, Billingham LJ. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Ann Oncol. 2015 Dec;26(12):2464-9. doi: 10.1093/annonc/mdv394. Epub 2015 Sep 25.
• Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim E, Swanton C, Billingham L. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature. 2020 Jul;583(7818):807-812. doi: 10.1038/s41586-020-2481-8. Epub 2020 Jul 15. Erratum In: Nature. 2020 Sep;585(7826):E21.

Helpful Links

• PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC) Middleton, G. et al. Journal of Thoracic Oncology, Volume 14, Issue 10, S7

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2015
• Primary Completion (Anticipated): September 1, 2023
• Study Completion (Anticipated): September 1, 2023

Study Registration Dates

• First Submitted: January 5, 2016
• First Submitted That Met QC Criteria: January 22, 2016
• First Posted (Estimate): January 27, 2016

Study Record Updates

• Last Update Posted (Estimate): May 11, 2023
• Last Update Submitted That Met QC Criteria: May 9, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: Lung Cancer; NSCLC; Adenocarcinoma; Matrix; SMP2; Umbrella Trial Design; Multi-arm
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms by Histologic Type; Neoplasms; Lung Diseases; Neoplasms by Site; Carcinoma; Neoplasms, Glandular and Epithelial; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Neoplasms, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Squamous Cell; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Immunological; Protein Kinase Inhibitors; Docetaxel; Palbociclib; Durvalumab; Osimertinib; Crizotinib
• Other Study ID Numbers: RG_14-072; 2014-000814-73 (EudraCT Number); ISRCTN38344105 (Other Identifier: ISRCTN Registry)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Study Data/Documents

1. Trial Website